HOME >> BIOLOGY >> NEWS
New drug enfuvirtide shows promise against drug resistant HIV infection

CHAPEL HILL -- The new drug enfuvirtide, a member of a new class of medications designed to combat HIV -- the virus that causes AIDS -- shows strong promise in treating drug-resistant cases of the life-threatening infection, a study conducted with patients in North and South America concludes.

A report on the research appears in the May 29 issue of the New England Journal of Medicine.

"This is one of the most important studies performed to date in HIV-infected patients who have already received highly active antiretroviral therapy (HAART) and a landmark study for the field of HIV," said Dr. Joseph Eron of the University of North Carolina at Chapel Hill and a report author.

"The clinical work clearly demonstrates that a completely new class of anti-HIV medication, developed by a local company, Trimeris, is highly effective in a very large randomized study," said Eron, associate professor of medicine at the UNC School of Medicine.

"Enfuvirtide, or T-20, works by blocking HIV entry into CD4 + lymphocytes or T-cells and will benefit patients who already have HIV that is resistant to current therapy."

CD4+ lymphocytes, also known as T-cells, are a key part of the body's immune system for fighting off disease-causing viruses, bacteria and various other organisms, he said. HIV is so deadly because it kills those defenders and leaves patients vulnerable to a wide variety of debilitating illnesses.

Fuzeon is enfuvirtide's trade name.

Another report of a second study with similar results carried out in Europe and Australia also appears in the May 29 issue of the journal. Eron and Dr. J. Michael Kilby of the University of Alabama at Birmingham have a third article in the journal describing T-20 and other drugs now in development in the new class of HIV medications called entry inhibitors.

Dr. Jacob P. Lalezari of Quest Clinical Research, Mount Zion Hospital and the University of California at San Francisco led
'"/>

Contact: David Williamson
919-962-8596
University of North Carolina at Chapel Hill
28-May-2003


Page: 1 2 3

Related biology news :

1. New study shows hope for treating inhalant abuse
2. Chemical derived from vitamin-E shows early promise as cancer drug
3. Cancer vaccine based on pathogenic listeria bacteria shows promise targeting metastases
4. Trial shows which brain cancer patients benefit from temozolomide
5. New research shows plants can shuffle and paste gene pieces to generate genetic diversity
6. Preclinical safety study shows adipose-derived stem cells improve heart function after heart attack
7. Simian virus 40 not associated with non-Hodgkin lymphoma, study shows
8. A probable cause for high blood pressure identified - shows links with diabetes
9. Blue marlin in gulf have high mercury levels, A&M study shows
10. New research shows air pollution can reduce childrens lung function
11. Pneumococcal vaccine reduces ear infections, pneumonia, new study shows

Post Your Comments:
(Date:2/5/2015)... IRVINE, Calif. , Jan. 27, 2015 ... trusted provider of globally deployed, innovative test ... today announced the delivery of its ... Martin Space Systems Company (LMSSC). GENASYS is ... the demands of mission-critical applications that require ...
(Date:2/5/2015)... , Jan. 30, 2015  It is gratifying ... power and potential for genomic science as a means ... disease prevention and treatment.  I was honored to participate ... government-funded precision medicine program. Since the ... science of genomics—from the first sequenced genome of a ...
(Date:1/22/2015)... 13, 2015 /PRNewswire/ - Today, FindBiometrics, the leading source of biometrics ... its new website design. "When we launched FindBiometrics ... Peter O,Neill , founder and CEO of FindBiometrics. "Now ... involvement from the key players on a very broad scale.  ...
Breaking Biology News(10 mins):Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 4J. Craig Venter, Ph.D., Co-Founder and CEO, Human Longevity, Inc. (HLI) Participates in White House Precision Medicine Event 2Identity Industry Leading Publication Debuts New Look As Biometrics Hit Mainstream 2
(Date:2/26/2015)... Feb. 26, 2015 DuPont Executive Vice President ... by key research advancements and product launches across the ... of America Merrill Lynch 2015 Global Agriculture Conference. ... building grain supplies the last two years, long-term demand ... pace of the last decade, when demand for corn ...
(Date:2/26/2015)... BioEnterprise today announced that Northeast ... $2 billion in growth funding during the past 13 ... sources, state – including the Ohio Third Frontier - ... has been raised in the past five years. ... the BioEnterprise Midwest Healthcare Growth Capital  Report.   ...
(Date:2/26/2015)... 2015 According to a new market ... For Transgenic Crops (Corn, Soybean, Cotton and Others), Synthetic ... Share, Growth, Trends and Forecast, 2013 – 2019,”the global ... in 2012 and is expected to reach USD 28,694.1 ... from 2013 to 2019. , Demand for food ...
(Date:2/26/2015)... Feb. 26, 2015  Epic Sciences announced today that ... present at the 35th Annual Cowen and Company Health ... the MIT Room, 3rd Floor. The conference will be ... Mass. Epic is developing diagnostic tests of ... and proteomic changes that occur during the course of ...
Breaking Biology Technology:DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 2DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 3DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 4DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 5More Than $2 Billion Invested in Northeast Ohio Bioscience Start-Up Companies Since 2002 2More Than $2 Billion Invested in Northeast Ohio Bioscience Start-Up Companies Since 2002 3More Than $2 Billion Invested in Northeast Ohio Bioscience Start-Up Companies Since 2002 4Global Agricultural Biotechnology Market is Expected to Reach USD 28,694.1 Million in 2019 : Transparency Market Research 2Global Agricultural Biotechnology Market is Expected to Reach USD 28,694.1 Million in 2019 : Transparency Market Research 3Epic Sciences to Present at 35th Annual Cowen and Company Health Care Conference 2
Cached News: